Scientists boost MeCP2-E1 by skipping e2 in Rett study
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Researchers at Texas Children's Duncan Neurological Research Institute and Baylor College of Medicine reported a strategy that skips the e2 segment of the MECP2 gene to boost production of the MeCP2‑E1 protein.
- Mouse models with the e2 segment removed showed a 50‑60% increase in MeCP2 protein levels.
- Patient‑derived cells carrying MECP2 mutations regained normal neuronal structure, electrical activity, and gene regulation after e2 deletion.
- Morpholinos designed to block the e2 segment raised MeCP2 protein in mice, but the authors note their toxicity and suggest antisense oligonucleotide therapies as a safer alternative.
- The study, published in Science Translational Medicine, was funded by the NIH, Howard Hughes Medical Institute, and other agencies.
Why it matters: The findings give families of children with Rett syndrome a concrete preclinical avenue to restore MeCP2 levels and neuronal function, while highlighting a therapeutic path that avoids morpholino toxicity and leverages antisense oligonucleotide strategies. The study provides preclinical proof that splicing modulation can improve neuronal function in Rett models.
